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Abstract
Purpose/Objective(s): To determine if intensity modulated radiation therapy (IMRT) in the post-operative setting for gastric
cancer was associated with reduced toxicity compared to 3D conformal radiation therapy (3DCRT).
Materials/Methods: This retrospective study includes 24 patients with stage IB-IIIB gastric cancer consecutively treated from
2001–2010. All underwent surgery followed by adjuvant chemoradiation. Concurrent chemotherapy consisted of 5-FU/
leucovorin (n = 21), epirubicin/cisplatin/5FU (n = 1), or none (n = 2). IMRT was utilized in 12 patients and 3DCRT in 12
patients. For both groups, the target volume included the tumor bed, anastomosis, gastric stump, and regional lymphatics.
Results: Median follow-up for the entire cohort was 19 months (range 0.4–8.5 years), and 49 months (0.5–8.5 years) in
surviving patients. The 3DCRT group received a median dose of 45 Gy, and the IMRT group received a median dose of
50.4 Gy (p = 0.0004). For the entire cohort, 3-year overall survival (OS) was 40% and 3-year disease free survival (DFS) was
41%. OS and DFS did not differ significantly between the groups. Acute toxicity was similar. Between 3DCRT and IMRT
groups, during radiotherapy, median weight lost (3.2 vs. 3.3 kg, respectively; p = 0.47) and median percent weight loss were
similar (5.0% vs. 4.3%, respectively; p = 0.43). Acute grade 2 toxicity was experienced by 8 patients receiving 3DCRT and 11
receiving IMRT (p = 0.32); acute grade 3 toxicity occurred in 1 patient receiving 3DCRT and none receiving IMRT (p = 1.0). No
patients in either cohort experienced late grade 3 toxicity, including renal or gastrointestinal toxicity. At last follow up, the
median increase in creatinine was 0.1 mg/dL in the IMRT group and 0.1 mg/dL in the 3DCRT group (p = 0.78).
Conclusion: This study demonstrates that adjuvant chemoradiation for gastric cancer with IMRT to 50.4 Gy was well-
tolerated and compared similarly in toxicity with 3DCRT to 45 Gy.
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Introduction
Gastric cancer (GC) accounts for 738,000 deaths worldwide and
10% of total annual cancer deaths [1]. Approximately 20,000
Americans will be diagnosed with GC this year, half of whom are
expected to die from the disease [2]. Thus, the development of
effective treatments with limited toxicity remains an area of active
interest.
In 2001, the Intergroup 0116 randomized trial demonstrated
both a relapse-free and overall survival (OS) benefit for the
addition of postoperative chemoradiotherapy over surgery alone
[3]. However, the benefit of radiotherapy (RT) is tempered by its
acute and late effects on adjacent vital organs, highlighting the
importance of developing techniques able to spare normal tissues
[4].
One such technique is Intensity Modulated Radiation Therapy
(IMRT), which utilizes intensity-modulated ‘‘beamlets’’ to con-
form dose away from vital organs and more closely towards tumor.
In comparison, three-dimensional conformal radiotherapy
(3DCRT) uses beams of uniform intensity, offering less freedom
in sculpting dose around the tumor. Prior dosimetric studies in GC
suggest the superior conformality of IMRT may reduce liver and
kidney radiation doses [5,6]. However, whether these dosimetric
advantages translate into meaningful clinical improvement is an
area of ongoing research.
The purpose of this study is to identify patients with GC who
underwent adjuvant chemoradiotherapy and report the compar-
ative outcomes of those treated with IMRT versus 3DCRT.
Materials and Methods
Our study was approved by the institutional review boards of
the University of Chicago Medical Center, University of Illinois at
Chicago Medical Center, and the Unversity of Illinois at Chicago
Cancer Center. All data was anonymized and individual patient
consent was not required as a waiver for the need for written
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informed consent was approved by the institutional review board
of each participating institution.
Patients
From October 2001 to January 2011, 24 consecutive patients
with Stage IB-IIIC GC or gastroesophageal junction cancer were
treated with adjuvant RT at the University of Chicago (UCMC)
and University of Illinois at Chicago Medical Center (UIMC).
Treatment
All patients underwent surgical resection. Surgery consisted of
subtotal gastrectomy in 12 patients, total gastrectomy in 10
patients, and esophagogastrectomy in 2 patients. The majority of
patients received 1 cycle of 5-fluorouracil (5FU) and leucovorin
followed by concurrent 5FU/leucovorin with radiation.
Radiation was delivered utilizing IMRT in 12 patients and
3DCRT in 12 patients. For both groups, the planning target
volume (PTV) included the tumor bed, anastomosis, gastric stump,
and regional lymphatics. In patients who received 3DCRT, the
total dose prescribed was 45 Gy in 1.8 Gy daily fractions. In
patients who underwent IMRT, four patients received a dose of
45 Gy, seven patients received 50.4 Gy and one patient received
54 Gy due to the presence of a positive surgical margin. Radiation
plans were developed on Eclipse (Varian, Palo Alto, U.S.A.) for 14
patients, Pinnacle (Philips, Amsterdam, Netherlands) for 5
patients, and CORVUS (Nomos, Pittsburgh, U.S.A.) for 5
patients. 3DCRT plans were delivered using 3 or more fields.
Patients were staged according to American Joint Committee on
Cancer (AJCC) 7th Edition 2010 tumor-node-metastasis (TNM)
Classification [7].
Data Collection
Maximal acute and late toxicity grade was scored according to
RTOG Acute Morbidity Scoring Criteria and Toxicity Criteria
and RTOG/EORTC Late Radiation Morbidity Scoring Schema,
respectively, with late toxicity defined as any toxicity occurring
greater than 3 months after treatment completion [8]. Acute
toxicities were recorded primarily from on-treatment visit notes,
while late toxicities were collected across departmental follow-up
notes.
Patients were seen at least once weekly while receiving RT, at
which point they were evaluated for acute toxicities. Patients were
then seen 4–6 weeks following treatment completion. Afterwards,
they were followed every 3–6 months for the first 2 years, and
every 6–12 months for the next 3 years. Imaging and bloodwork
were drawn at similar intervals.
Statistics
Clinical-pathologic variables of the 2 cohorts were statistically
analyzed using JMP version 9 (SAS Institute). All tests of statistical
significance were two-sided, and significance was defined as a
value of p,0.05. The log rank test was used to compare toxicities
between IMRT and 3DCRT. Survival estimates were obtained
using the Kaplan-Meier method. Outcome parameters were
defined as: OS: time of surgery to time of death or last known
follow-up; disease free survival (DFS). All events were calculated
using standard life table methods, and the differences were
compared using Cox regression models.
To estimate the power to detect an association using a Cox
proportional hazards model, two simulated data sets of size 12
were generated. The first simulated data set was exponentially
distributed with rate parameter 1, and the second simulated data
set was exponentially distributed with rate parameter log(HR),
where HR is the target hazard ratio. Censoring times were also
generated as exponential random variables such that approxi-
mately 50% of the data points were censored. This process was
repeated 10,000 times for each target hazard ratio. For each of the
10,000 simulated data sets, a Cox proportional hazards model was
used to test the null hypothesis of no difference between the two
groups. The power was estimated to be the number of times the p-
value associated with this null hypothesis was less than 0.05.
Results
Median follow up for the entire cohort was 19 months (range
0.4–8.5 years), and 49 months (0.5–8.5 years) in surviving patients.
Median follow up was similar in those receiving IMRT vs.
3DCRT (24.3 vs. 16.0 months, p = 0.63).
Table 1 describes patient and tumor characteristics. There were
no statistically significant differences in mean age, gender
distribution, tumor grade, and TNM or overall AJCC stage.
Table 2 describes treatment characteristics. The 3DCRT group
received a median dose of 45 Gy, and the IMRT group received a
median dose of 50.4 Gy (p = 0.0004). Otherwise, both groups
shared a statistically similar distribution of type of surgery
Table 1. Patient Characteristics.
3DCRT (n = 12) IMRT (n = 12) p-value





Grade 1 1 2
Grade 2 5 2



















AJCC = American Joint Committee on Cancer; 3DCRT = 3-dimensional conformal
radiotherapy; IMRT = intensity modulated radiotherapy.
*Two patients in the IMRT group did not have tumor grade documented in
pathology report.
doi:10.1371/journal.pone.0082642.t001
IMRT versus 3DCRT for Gastric Cancer
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Table 2. Treatment Characteristics.
3DCRT (n = 12) IMRT (n = 12) p-value
Surgery Type Esophagogastrectomy 2 0 0.58
Total gastrectomy 5 5
Subtotal gastrectomy 5 7
Margin Status Negative 6 7 0.30
,3 mm 3 0
Positive 3 4
Not recorded 0 1
Extent of node dissection D1 3 3 0.63
D2 8 4
Not recorded 1 5




45 Gy 12 4
$50.4 Gy 0 8
3DCRT = 3-dimensional conformal radiotherapy; IMRT = intensity modulated radiotherapy; ECF = epirubicin, cisplatin, 5FU.
¥Difference between median dose.
doi:10.1371/journal.pone.0082642.t002
Figure 1. Disease-Free Survival.
doi:10.1371/journal.pone.0082642.g001
IMRT versus 3DCRT for Gastric Cancer
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received, surgical margin status, extent of node dissection, type of
concurrent chemotherapy.
For the entire cohort, 3-year DFS was 40.6% (Figure 1) and 3-
year OS was 40.0% (Figure 2). OS and DFS were similar between
the IMRT and 3DCRT groups.
Table 3 describes RT-related acute and late toxicity. Regarding
acute toxicities, median weight lost from the first to last week of
RT was 3.2 kg in the 3DCRT group and 3.3 kg in the IMRT
group (p = 0.47). The median percent weight loss over the same
period was also similar (5.0% in the 3DCRT group and 4.3% in
the IMRT group, p = 0.43). There were two acute grade 3
toxicities. One patient who received 3DCRT became feeding-tube
dependent, and one patient who received IMRT required
esophageal dilatation 1 month after completing RT. Acute normal
tissue toxicities are detailed in Table 4.
Regarding long term toxicities, there were no patients in either
cohort, who experienced grade 3 long term renal toxicity. At last
follow up, the median increase in serum Cr was 0.1 mg/dL in the
IMRT group and 0.1 mg/dL in the 3DCRT group (p = 0.78).
There were no late grade 3 gastrointestinal toxicities in either
group. Late normal tissue toxicities are detailed in Table 5.
Discussion
This study compares the outcomes of patients with GC treated
with postoperative IMRT versus a similar cohort treated with
postoperative 3DCRT. Overall, toxicity rates were comparable
between cohorts, though patients receiving IMRT received a
higher median dose. There were no differences between cohorts in
regards to OS or DFS.
Figure 2. Overall Survival.
doi:10.1371/journal.pone.0082642.g002
Table 3. Acute Radiation Morbidity.
3DCRT (n = 12) IMRT (n = 12) p-value
Median weight loss through radiotherapy (kg) 3.2 3.3 0.47
Median percent body weight loss through radiotherapy 5.0% 4.3% 0.43
No. patients with acute grade 2 toxicities 8 11 0.32
No. patients with acute grade 3 toxicities 1 0 1.00
No. patients with late grade 2 toxicities 1 3 0.59
No. patients with late grade 3 toxicities 0 0 NS
Median serum creatinine increase (mg/dL) 0.1 0.1 0.78
doi:10.1371/journal.pone.0082642.t003
IMRT versus 3DCRT for Gastric Cancer
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Prior series have suggested a potential role for IMRT in the
adjuvant treatment of GC. In 2009, investigators from Germany
reported the outcomes of two sequentially treated GC cohorts,
with 27 patients treated with 3DCRT from 2001–2005, and 33
patients treated with IMRT from 2002–2007; the majority of both
the 3DCRT and IMRT groups received 45 Gy (68% vs. 91%,
respectively, p = NS) [9]. Median OS (18 months vs. not reached,
p = 0.0492) and DFS (13 months vs. not reached, p = 0.0216)
favored the IMRT cohort. Actuarial 2-year OS also statistically
favored the IMRT group (67% vs. 37%, p = 0.0492). Dosimetric
parameters suggested that this benefit may be attributed to IMRT
allowing for larger PTVs (mean 1,397 vs. 1,768 cm3, p = 0.0368),
while maintaining lower V30 parameters for the left (mean 26.8%
vs. 19.5%, p = 0.0015) and right kidneys (mean 11.6 vs. 15.6%,
p = 0.0170). Reduced renal irradiation was associated with
statistically lower creatinine 6 weeks post-RT for the IMRT
group (mean 0.71 vs. 0.84 mmol/L, p = 0.0210). However,
creatinine values were similar at last follow-up and no late renal
toxicity grade 3–4 (LENT-SOMA scale) was observed in either
cohort. Of note, the results of this study are complicated by the
two groups having received varied chemotherapy regimens, with
96% of the 3DCRT group receiving 5FU/folinic acid and 70% of
the IMRT group receiving oxaliplatin/capecitabine (p,0.0001).
A more recent series from Stanford University also demonstrat-
ed IMRT to have a more favorable toxicity profile [10]. In 26
patients who received 3DCRT versus 31 patients who received
IMRT, more patients receiving 3DCRT required a treatment
break (3 days vs. 0, no p-value reported). Regarding late toxicity,
at a median follow-up of 1.4 years, the median serum creatinine
was unchanged for patients treated with IMRT (0.80 mg/dL),
whereas it had increased 0.20 mg/dL in those receiving 3DCRT
(0.80 to 1.0 mg/dL, p = 0.02). However, IMRT was not associated
with a clear dosimetric advantage, as the median kidney V20 was
statistically similar between the IMRT and 3D CRT groups
(17.5% vs. 22%, respectively, p = 0.17). As in our series, differences
in hepatotoxicity between those receiving 3DCRT versus IMRT
were not detected, though median liver V30 was reduced in the
IMRT group (16.1 and 28%, p,0.001). In contrast to the
previously discussed series from Germany, disease outcomes
between the 3DCRT and IMRT groups were similar; 2-year
OS (51 vs. 65%, p = 0.5), DFS (60% vs. 54%, p = 0.8), and local
control (83% vs. 81%, p = 0.9), respectively.
In this study, there were no detected differences in toxicity or
disease control despite the IMRT cohort having received a higher
median dose (50.4 Gy vs. 45 Gy, p = 0.0004) than the 3DCRT
cohort. This dose is also higher than that received by the IMRT
cohorts of the two previously discussed studies. Potentially, if our
entire 3DCRT cohort was prescribed 50.4 Gy, then indeed
toxicity rates may have been different. This is suggested by our
prior dosimetric analysis, in which patients were planned to
receive 50.4 Gy using either two- or three-field 3DCRT versus
IMRT [6]. Compared with the three-field plan, IMRT signifi-
cantly reduced liver V30 dose (63.6% vs. 18.9%, p = 0.010), as
well as right kidney V20 dose (20.9% vs. 11.6%, p = 0.027).
Dosimetric studies analyzing the feasibility of IMRT vs.
3DCRT in GC suggest that neither modality is categorically
superior, but that individual patient anatomy should dictate the
choice. In a study from the University of Toronto where both 5-
field 3DCRT and IMRT plans were created and evaluated by
gastrointestinal radiation oncologists, IMRT was preferred in 17 of
19 cases (89%) [11]. Similarly while IMRT was dosimetrically
rated higher for kidney sparing in 69% of the reviewers’ ratings,
conversely 31% considered 3DCRT better able to spare the
kidneys. Therefore, it stands to reason that the decision between
the two modalities should likely be individualized. Figures 3A and
3B pictorially highlight the dosimetric characteristics of 3DCRT
and IMRT, respectively, in two patients treated adjuvantly for
GC. While 3DCRT generally spreads low-dose radiation across a
smaller body volume, IMRT better conforms high-dose radiation
towards tumor and away from normal tissues.
When neither modality is dosimetrically superior, 3DCRT
should be encouraged, as it holds other advantages over IMRT.
3DCRT typically irradiates a smaller volume of normal tissue by
distributing its dose through fewer beams, has less interleaf scatter
dose, and utilizes fewer monitored units. In addition, 3DCRT may
also better treat tumors subject to intrafraction motion. The sub-
diaphragmatic location of the gastric bed subjects it to respiratory
motion, and investigators from Fudan University recently reported
a mean superior-inferior intrafraction respiratory motion of
11.1 mm in 22 patients treated with postoperative RT for GC
[12]. Because IMRT delivers dose through smaller beam
apertures, there is an increased risk of intrafraction miss for
patients whose tumors move significantly. Finally, there are
substantial medical cost savings when using 3DCRT over IMRT.
These differences should encourage the individualized evaluation
of both modalities.
Our study is limited by biases inherent in any retrospective
review. However, in contrast to prior series, our study population
was not preferentially treated with IMRT despite its availability.
Rather, patients were treated with IMRT and 3DCRT contem-
poraneously, with 8 of 12 patients treated with 3DCRT after 2006,
potentially eliminating bias associated with treating across different
Table 4. RTOG Acute Radiation Morbidity Grade Detail.











IMRT 3 1 4
3DCRT 4 1 5
Upper
gastrointestinal
IMRT 9 0 9
3DCRT 4 0 4
doi:10.1371/journal.pone.0082642.t004
Table 5. EORTC/RTOG Late Effects Grade Detail.
Grade 2 Grade 3
Total grade
$2
(No. patients) (No. patients) (No. patients)
Esophagus IMRT 1 0 1
3DCRT 0 0 0
Small/Large
Intestine
IMRT 0 0 0
3DCRT 1 0 1
Kidney IMRT 3 0 3
3DCRT 1 0 1
Liver IMRT 0 0 0
3DCRT 0 0 0
doi:10.1371/journal.pone.0082642.t005
IMRT versus 3DCRT for Gastric Cancer
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eras. Another study limitation is that a range of tumor stages/
grades were included in our patient population, though there was
no statistical difference between groups.
Furthermore, we performed a retrospective power analysis,
determining our study size has a power of 0.12 to detect a hazard
ratio of at least 1.5 in regards to overall survival. Thus, our study is
not powered to reveal significant differences between the groups
regarding disease outcomes. However, we believe our results
remain worthwhile, as they further quantify the clinical magnitude
of nephrotoxicity post-RT, agreeing with prior series that median
creatinine increases are small, an important consideration for a
patient population that may require systemic therapy in the future.
Additionally, our results reiterate that should IMRT reduce
nephrotoxicity, this advantage may also be small; in the series from
Stanford, creatinine increased by 0.0 mg/dL for IMRT vs.
0.2 mg/dL for 3DCRT (p = 0.02), and in the series from
Germany, there was no statistical difference in creatinine at 1
year or at last follow-up between RT modalities. In our series, both
groups experienced a median creatinine increase of 0.1 mg/dL
(p = 0.78). Furthermore, while kidneys do not respond acutely to
radiation, we believe our median follow-up of 19 months should
capture radiation nephropathy, as such changes have been
detected at 6 months [4]. Finally, we believe our results are
noteworthy, as they agree with available dosimetric studies. As
noted in the series from Stanford reporting reduced creatinine
levels with IMRT, V20 and mean kidney radiation doses were not
statistically lowered with IMRT. Instead, IMRT was associated
with a significant increase in right mean kidney dose (11.9 Gy vs
10.54 Gy, p = 0.04). Finally, given the decline of GC incidence
and that less than half of patients eligible are currently referred for
adjuvant RT [13], future retrospective series on this topic will
likely feature small numbers of patients as well.
In conclusion, this analysis revealed that patients treated with
IMRT to a total dose of 50.4 Gy tolerated their treatment well and
had long term outcomes similar to a cohort treated with 3DCRT
to 45 Gy. The decision between IMRT and 3DCRT will vary by
patient anatomy, for which individual comparison plans should be
considered.
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